Articles by Patricia Van Arnum - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Patricia Van Arnum

Watson Completes Acquisition of Actavis, Will Take Actavis Name

Nov 7, 2012

Watson Pharmaceuticals has completed its EUR 4.25 billion ($5.4 billion) acquisition of the Actavis Group. The combination creates the world's third largest generic-drug pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion, according to Watson.

Ben Venue Resumes Limited Production

Oct 23, 2012

Ben Venue Laboratories has resumed production on a limited number of manufacturing lines in the company's Bedford, Ohio, facilities.

Merck Serono Launches New Spin-off Company; Provides Update on Restructuring

Oct 3, 2012

Merck Serono's Asceneuron is the third company to be spun off from the company's Entrepreneur Partnership Program that was launched to mitigate the impact from recent restructuring at its Geneva site.

A Manufacturing-Capacity Sharing Model

The manufacturing capacity-sharing model between Merck and MedImmune ushers in a new paradigm of "co-opetition."
Oct 1, 2012

The manufacturing capacity-sharing model between Merck and MedImmune ushers in a new paradigm of "co-opetition."

Bristol-Myers Squibb Issues Voluntary Recall of Carmustine for Overfilled Vials

Sep 4, 2012

Bristol-Myers Squibb has initiated a voluntary recall of 10 lots of BiCNU (carmustine for injection) previously manufactured by Ben Venue Laboratories, a former, third-party contract manufacturer for the company, to the user level.

Myriad Genetics Receives Favorable Ruling on Gene Patentability

Aug 22, 2012

Myriad Genetics reported that a US federal appeals court has ruled that the company's composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under federal patent law. The court, however, denied the company's effort to patent methods of "comparing" or "analyzing" DNA sequences.

Eli Lilly Receives $1.3 Billion Following Bristol-Myers Squibb's Acquisition of Amylin Pharmaceuticals

Aug 22, 2012

Eli Lilly has received $1.3 billion for payment of financial obligations from Amylin Pharmaceuticals following Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals earlier this month.

Pfizer Settles with DOJ and SEC on Improper Conduct in Select Emerging Markets

An internal investigation and voluntary disclosure by Pfizer led to a settlement with the US Department of Justice and Securities and Exchange Commission.
Aug 7, 2012

An internal investigation and voluntary disclosure by Pfizer led to a settlement with the US Department of Justice and Securities and Exchange Commission.

Bristol-Myers Squibb Agrees to Acquire Amylin for $5.3 Billion

Jul 2, 2012

Bristol-Myers Squibb has agreed to acquire the biopharmaceutical company Amylin Pharmaceuticals for a purchase price of $5.3 billion and an additional $1.7 billion for assuming Amylin's net debt and a contractual payment obligation to Eli Lilly based on Amylin's recently terminated agreement with Eli Lilly over the diabetes drug exenatide.

ADVERTISEMENT

ADVERTISEMENT

Click here